Johnson & Johnson $JNJ Shares Sold by Bowen Hanes & Co. Inc.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bowen Hanes & Co. Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 38,554 shares of the company's stock after selling 2,092 shares during the quarter. Bowen Hanes & Co. Inc.'s holdings in Johnson & Johnson were worth $6,394,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Elios Financial Group Inc. grew its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares during the last quarter. Atlantic Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares during the last quarter. MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. grew its stake in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc increased its position in Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after buying an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.7890 during mid-day trading on Wednesday, reaching $178.5890. 9,028,878 shares of the company's stock were exchanged, compared to its average volume of 8,462,277. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a 50-day simple moving average of $162.59 and a two-hundred day simple moving average of $158.87. The company has a market cap of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $180.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company earned $2.82 earnings per share. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Finally, Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.